Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells 172,899 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 172,899 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $37.17, for a total value of $6,426,655.83. Following the transaction, the insider owned 18,630,739 shares of the company’s stock, valued at approximately $692,504,568.63. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The shares were sold at an average price of $36.48, for a total value of $5,280,698.88.
• On Thursday, August 20th, Mayukh Sukhatme sold 17,519 shares of Roivant Sciences stock. The stock was sold at an average price of $37.30, for a total value of $653,458.70.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total value of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Stock Down 1.5%

NASDAQ:ROIV traded down $0.54 on Friday, reaching $36.30. 6,185,493 shares of the company’s stock were exchanged, compared to its average volume of 5,631,176. The firm has a market capitalization of $26.22 billion, a price-to-earnings ratio of -68.49 and a beta of 1.12. Roivant Sciences Ltd. has a 52-week low of $11.60 and a 52-week high of $37.97. The business has a fifty day moving average of $34.61 and a 200-day moving average of $30.43.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. As a group, equities analysts anticipate that Roivant Sciences Ltd. will post -2 earnings per share for the current year.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of ROIV. Goldman Sachs Group Inc. raised its stake in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after buying an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after acquiring an additional 34,341 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Roivant Sciences by 1.9% during the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after acquiring an additional 1,689 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Roivant Sciences by 149.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock valued at $129,000 after acquiring an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp increased its holdings in shares of Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after acquiring an additional 1,181 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Thursday, August 6th. Guggenheim boosted their target price on Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Bank of America restated a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Finally, HC Wainwright lifted their price objective on Roivant Sciences from $34.00 to $41.00 and gave the company a “buy” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $35.14.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.